Twin Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Twin Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-16,778	Closed	-$1.85M	–	287
2020 Q2	$1.85M	Sell	16,778 -1,240	-7%	-$137K	0.18%	154
2020 Q1	$1.8M	Sell	18,018 -350	-2%	-$45.3K	0.19%	148
2019 Q4	$2.74M	Sell	18,368 -7,450	-29%	-$1.01M	0.23%	134
2019 Q3	$3.31M	Sell	25,818 -2,092	-7%	-$280K	0.24%	138
2019 Q2	$3.98M	Buy	+27,910	New	+$3.75M	0.28%	127
2016 Q3	–	Sell	-10,391	Closed	-$1.47M	–	362
2016 Q2	$1.47M	Buy	+10,391	New	+$1.53M	0.11%	245

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Twin Capital Management's JAZZ Position: Q3 2020 in Review

Twin Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2020, closing a stake of 16,778 shares — an estimated $1.85M sold.

Twin Capital Management first reported a position in JAZZ in Q2 2016 and held it in 6 quarters. The position peaked at $3.98M in Q2 2019. 389 funds tracked by Wall St. Rank hold JAZZ as of Q3 2020.

Twin Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Twin Capital Management sold 16,778 Jazz Pharmaceuticals shares in Q3 2020, an estimated $1.85M.
Twin Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 6 quarters.
Twin Capital Management's Jazz Pharmaceuticals position peaked at $3.98M in Q2 2019.
389 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2020.

Based on Twin Capital Management's 13F filing for Q3 2020, filed 5 Nov 2020.